Abrégé

The present invention discloses a composition(s) of hydrophobic plant molecule(s) and/or extract(s) with enhanced bioavailability comprising hydrophobic active and synergetic mixture of lecithin and lysolecithin and to the process for preparation thereof. More specifically, a composition for use in a therapeutic formulation, comprising: a synergistic mixture comprising from about 5% to about 25% of lecithin; and from about 75% to about 95% of lysolecithin, based on the combined weight of said lecithin and said lysolecithin; in combination with a hydrophobic active ingredient.

Classes IPC  ?

• A61K 36/9066 - Curcuma, p. ex. curcuma, zédoaire ou curcuma amada
• A61K 31/4738 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides

Abrégé

The present invention discloses a novel method of inhibiting the Beta-secretase enzyme by using Bis-O-demethylcurcumin. The present invention further discloses the prevention, management and treatment of Alzheimer's disease (AD) by the inhibition of Beta-secretase in a patient using Bis-O-demethylcurcumin. The present invention also discloses the process of synthesizing Bis-O-demethylcurcumin and the compositions comprising the same.

Classes IPC  ?

• A61K 36/9066 - Curcuma, p. ex. curcuma, zédoaire ou curcuma amada

Abrégé

A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.

Classes IPC  ?

• A61K 36/9066 - Curcuma, p. ex. curcuma, zédoaire ou curcuma amada
• A61K 9/51 - Nanocapsules
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/10 - DispersionsÉmulsions
• A61K 9/107 - Émulsions
• A61K 36/9068 - Zingiber, p. ex. gingembre
• A61K 36/16 - Gynkgophyta, p. ex. Ginkgoaceae (famille du ginkgo)
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61K 36/258 - Panax (ginseng)
• A61K 36/38 - Clusiaceae, Hypericaceae ou Guttiferae (famille de l'Hypericum ou du mangoustan), p. ex. millepertuis
• A61K 36/53 - Lamiaceae ou Labiatae (famille de la menthe), p. ex. thym, romarin ou lavande
• A61K 31/12 - Cétones
• A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
• A61K 31/05 - Phénols
• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
• A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine

Abrégé

The present invention discloses novel highly bioavailable, water soluble, sustained release nanoformulation(s) comprising unique proportion of the hydrophobic plant derived compound(s) in an emulsifier phase and aqueous phase to achieve the sustained release over a 24hr time period and more. The present invention further discloses process for preparation of said novel water soluble, highly bioavailable and sustained release nanoformulation thereof.

Classes IPC  ?

• A61K 9/107 - Émulsions

Abrégé

A pharmaceutical composition(s) for ophthalmic/nasal administration comprising; one or more nano emulsified Curcumin component(s) and/or its metabolites selected from natural or synthetic curcuminoid(s); in combination with a pharmaceutically acceptable excipient(s), effective in increasing the bioavailability of the active compounds is disclosed herein.

Classes IPC  ?

• A01N 35/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant deux liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. un radical aldéhyde
• A61K 31/12 - Cétones

Abrégé

Aqueous ophthalmic compositions comprising natural or synthetic curcuminoids either alone or in combination, nonionic surfactant and co-solvent along with suitable ophthalmic excipients, effective in increasing the bioavailability of the active compounds when administered topically to the eye is disclosed herein.

Classes IPC  ?

• A61K 36/9066 - Curcuma, p. ex. curcuma, zédoaire ou curcuma amada
• A61K 31/12 - Cétones
• A61K 9/10 - DispersionsÉmulsions

Abrégé

A process for nanomulsification of highly lipophillic polyphenols compounds using non- ionic surfactant and a non-ionic co-solvent with the help of sonar energy, to enhance the aqueous solubility is disclosed herein.

Classes IPC  ?

• A61K 9/10 - DispersionsÉmulsions
• A61K 31/12 - Cétones
• A61K 36/9066 - Curcuma, p. ex. curcuma, zédoaire ou curcuma amada

Abrégé

Nanoemulsified topical formulation comprising curcumin, tetrahydroxycurcumin (BDMC) and curcuminoid either alone or in combinations in an amount of 0.001 % to 50% together with one or more pharmaceutically, nutraceutically or dietetically acceptable excipient(s) or inactive ingredients, useful for the treatment of inflammation, various skin disorders, mucosal disorders and other diseases associated or related thereof.

Classes IPC  ?

• A61K 36/906 - Zingiberaceae (famille du gingembre)

Abrégé

The invention discloses a compound of formula (I) wherein, at least one of R1, R2, R3 and R4 is -C(=O)Rn and R1, R2 R3 and R4 are H or CH3 and Rn is alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis form or trans form or both. In Rn, where n is 12 to 30 carbons; and pharmaceutically acceptable salt thereof. The said alkenyl groups are preferably selected from the group consisting of eicosapentaenoic acid (EPA) or DHA (docosahexaenoic acid). This invention further discloses processes for their preparation of compounds of formula I and pharmaceutical compositions that contain these compounds.

Classes IPC  ?

• C07C 69/587 - Esters d'acides monocarboxyliques avec plusieurs liaisons doubles carbone-carbone
• C07C 67/18 - Préparation d'esters d'acides carboxyliques par conversion d'un groupe contenant de l'azote dans un groupe ester
• A61K 31/23 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone